| Not Yet Recruiting | Speculum-Free Intravitreal Injection Using Cotton-Tipped Applicator Retraction: A Randomized Trial of Pain, Pr NCT07481500 | Jakkrit Juhong | N/A |
| Not Yet Recruiting | Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular NCT07516132 | Ocular Therapeutix, Inc. | Phase 3 |
| Recruiting | Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related M NCT07482176 | Adverum Biotechnologies, Inc. | Phase 3 |
| Not Yet Recruiting | A Clinical Study of QL1207H Injection Versus Aflibercept for Neovascular Age-related Macular Degeneration NCT07489586 | Qilu Pharmaceutical Co., Ltd. | Phase 3 |
| Not Yet Recruiting | To Evaluate the Safety, Pharmacokinetics, and Efficacy of GB10 Intravitreal Injection in Patients With Neovasc NCT07406438 | Shenzhen Kexing Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) NCT07317934 | Innostellar Biotherapeutics Co.,Ltd | Phase 3 |
| Not Yet Recruiting | Therapeutic Prospects of Faricimab Injection for Patients Affected by Neovascular Age-Related Macular Degenera NCT07088445 | Hui Peng | — |
| Recruiting | Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Rel NCT07064759 | 4D Molecular Therapeutics | Phase 3 |
| Not Yet Recruiting | A Phase 3 Clinical Trial to Compare RBS-001 to Eylea® in Subjects With Neovascular Age-Related Macular Degener NCT06470373 | Rophibio, Inc. | Phase 3 |
| Active Not Recruiting | A Study to Learn More About the Use of Aflibercept in Routine Medical Practice in Japanese Participants With N NCT06929143 | Bayer | — |
| Not Yet Recruiting | Open-laBel Dose-escalation Study for CRISPR/cas13- Rna TargetInG THerapy for the Treatment of Neovascular Age- NCT06623279 | HuidaGene Therapeutics Co., Ltd. | Phase 1 |
| Active Not Recruiting | A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Re NCT06795048 | Hoffmann-La Roche | Phase 4 |
| Recruiting | Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related M NCT06856577 | Adverum Biotechnologies, Inc. | Phase 3 |
| Not Yet Recruiting | This Project At LMU Looks At How Using AI 2nd Opinion Report to Analyze Retinal Eye Scans Impact Doctors' Deci NCT06817915 | Johannes Schiefelbein | N/A |
| Withdrawn | An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age NCT06398080 | Regeneron Pharmaceuticals | — |
| Completed | Durability of Three Monthly Loading Doses With Faricimab in Treatment-naïve Neovascular Age-related Macular De NCT06890026 | Rigshospitalet, Denmark | — |
| Active Not Recruiting | A Long-term Follow up Study of EXG102-031 in Patients With wAMD (Everest LTFU) NCT06817343 | Exegenesis Bio | Phase 1 |
| Recruiting | Trial to Evaluate the Safety and Efficacy of EB-203 in Patients With Neovascular Age-related Macular Degenerat NCT06487039 | EyebioKorea, Inc. | Phase 2 |
| Completed | Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS) NCT05989126 | Regeneron Pharmaceuticals | Phase 3 |
| Active Not Recruiting | The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Vis NCT06075147 | Bayer | — |
| Active Not Recruiting | Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration NCT06116890 | Kyowa Kirin Co., Ltd. | Phase 2 |
| Recruiting | Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD) NCT05769153 | Alcon Research | Phase 1 / Phase 2 |
| Recruiting | Safety and Tolerability of OCU-10-C-110 for Injection in Subjects With Neovascular Age-related Macular Degener NCT05904691 | Ocugenix Corporation | Phase 1 |
| Recruiting | CRISPR/cas13-medIated RNA TarGeting THerapy for the Treatment of Neovascular Age-related Macular Degeneration NCT06031727 | HuidaGene Therapeutics Co., Ltd. | EARLY_Phase 1 |
| Completed | Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial Kit NCT05282004 | Sandoz | Phase 3 |
| Completed | Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Prefilled Syringe NCT05161806 | Sandoz | Phase 3 |
| Completed | Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients Wi NCT05269966 | Novartis Pharmaceuticals | Phase 4 |
| Enrolling By Invitation | Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMD NCT05210803 | AbbVie | — |
| Active Not Recruiting | A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System NCT04657289 | Hoffmann-La Roche | Phase 3 |
| Terminated | Observational Study to Evaluate Fluid Resolution and Effectiveness of Brolucizumab for nAMD in Portugal NCT04764656 | Novartis Pharmaceuticals | — |
| Terminated | Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration NCT04746963 | AsclepiX Therapeutics, Inc. | Phase 1 / Phase 2 |
| Completed | Observational Study to Evaluate Fluid Resolution and Effectiveness in Patients Receiving Beovu in Neovascular NCT04543331 | Novartis Pharmaceuticals | — |
| Active Not Recruiting | RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Ma NCT04514653 | AbbVie | Phase 2 |